anti-neutrophil cytoplasmic antibody

Anti-neutrophil cytoplasmic antibody is an antibody that reacts with lysosomal enzymes in the cytoplasm of neutrophils and monocytes, and is a group of human neutrophil cytoplasmic components as target antigens, Autoantibodies that are closely related to a variety of small vascular inflammatory diseases. ANCA was first discovered in sera in patients with necrotizing glomerulonephritis in 1982. Indirect immunofluorescence studies have shown that there are two models of neutrophil cytoplasmic antibody fluorescent staining. Cytoplasmic (cANCA) and perinuclear (pANCA) ANCA have important clinical effects on systemic vasculitis and inflammatory bowel disease. Diagnostic significance. Basic Information Specialist classification: cardiovascular examination classification: blood examination Applicable gender: whether men and women apply fasting: fasting Analysis results: Below normal: Normal value: no Above normal: negative: normal. Positive: No relevant information. Tips: After 8 pm on the day before the medical examination, you should start fasting for 12 hours. Normal value negative. (Note the specific reference value depends on each laboratory.) Clinical significance Abnormal results ANCA is considered to be a specific serum marker for primary vasculitis. ANCA-positive most common diseases such as Wegenersgranulomatosis (WG), primary focal segmental necrotic glomerulonephritis (idiopathicfocalsegmentalnecrotizingglomerulomephritis, IFSNGN), crescentic glomerulonephritis (NCGN), nodules ANCA can be detected in polyarteritis (PAN). The positive rate of cANCA in WG can be as high as 90%, and anti-PR3 antibody positive is a specific indicator for diagnosing WG. In patients with necrotic or crescentic glomerulonephritis, the positive rate of ANCA can reach 80%, and the specific antigen corresponding to pANCA is mainly MPO. The detection of ANCA can greatly improve the early diagnosis rate of renal vasculitis. ANCA is an important indicator for the diagnosis, efficacy observation, disease activity and recurrence of patients with primary vasculitis. Many studies have shown that the serum titer of ANCA in patients with primary vasculitis is associated with disease activity, and the ANCA titer is increased or continuously increased, suggesting that the disease worsens or recurs after remission. The increase in ANCA titer often occurs before the disease recurs, so dynamic monitoring of ANCA is important for predicting disease recurrence. The diseases associated with ANCA are also secondary vasculitis, non-vascular inflammatory diseases (such as pulmonary inflammatory diseases), inflammatory ulcers (IBD), rheumatoid arthritis, disseminated lupus erythematosus, autoimmune Hepatitis, etc. However, the related ANCA target antigens in these diseases are different, and different antigen-antibody systems are associated with different diseases, so the detection of specific target antigens of ANCA is more conducive to clinical diagnosis. Need to check the skin of people with large areas of inflammation. Positive results may be diseases: systemic vasculitis, hormone-resistant asthma, pediatric rapid glomerulonephritis, tubulointerstitial nephritis uveitis syndrome, systemic vasculitis-induced neurological damage, cutaneous leukocyte vasculitis Precautions Abnormal people: generally no special population. Forbidden before examination: Please inform the doctor about the recent medication and special physiological changes before the test. 1, do not eat too greasy, high-protein food the day before the blood, to avoid heavy drinking. The alcohol content in the blood directly affects the test results. 2. After 8 pm on the day before the medical examination, you should start fasting for 12 hours to avoid affecting the test results. Requirements for examination: When taking blood, you should relax your mind, avoid the contraction of blood vessels caused by fear, and increase the difficulty of blood collection. Inspection process Indirect immunofluorescence: fluorescein is labeled on the corresponding [de] antibody and directly reacts with the corresponding antigen. In the first step, an unknown unlabeled [de] antibody (sample to be tested) is added to a known antigen sample, and incubated at 37 ° C for 30 min in a wet box to fully bind the antigen antibody, followed by washing to remove unbound [de] antibody. . In the second step, a fluorescently labeled [de]antiglobulin antibody or an anti-IgG, IgM antibody is added. If an antigen-antibody reaction occurs in the first step, the labeled [de] anti-globulin antibody is further bound to the bound antigen [de] antibody, thereby identifying an unknown antibody. Not suitable for the crowd There are no special taboos. Adverse reactions and risks There are no related complications and hazards.

The material in this site is intended to be of general informational use and is not intended to constitute medical advice, probable diagnosis, or recommended treatments.